NextPlat (NXPL) Gross Margin (2015 - 2026)
NextPlat's (NXPL) quarterly Gross Margin came in at 39.51% in Q2 2026, up 1773.0% year-over-year from 2.11% in Q2 2025, and up 14.11% quarter-over-quarter from 34.62% in Q1 2026.
Analysis
NextPlat (NXPL) Gross Margin (2015 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Gross Margin for 12 consecutive years, with 39.51% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Gross Margin rose 1773.0% year-over-year to 39.51% in Q2 2026; TTM through Jun 2026 was 26.23%, a 575.0% increase from a year earlier, with the FY2025 full-year figure at 20.08%, down 566.0% from the prior year.
- Gross Margin was 39.51% for Q2 2026 at NextPlat, up from 34.62% in the prior quarter.
- Over five years, Gross Margin peaked at 39.51% in Q2 2026 and troughed at 14.29% in Q4 2025.
- A 5-year average of 24.96% and a median of 22.77% in 2024 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin plunged 1482 bps in 2024 and surged 1773 bps in 2026, its largest moves.
- Over 5 years, Gross Margin stood at 16.8% in 2022, then surged by 88 bps to 31.64% in 2023, then tumbled by 47 bps to 16.81% in 2024, then retreated by 15 bps to 14.29% in 2025, then surged by 176 bps to 39.51% in 2026.
- The last three Gross Margin figures came in at 39.51% (Q2 2026), 34.62% (Q1 2026), and 14.29% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 51.98% |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 38.77% |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 46.52% |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 42.01% |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 73.60% |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 62.35% |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 4.68% |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 50.83% |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 95.97% |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 39.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.51% |
| Mar 31, 2026 | 34.62% |
| Dec 31, 2025 | 14.29% |
| Sep 30, 2025 | 19.85% |
| Jun 30, 2025 | 21.77% |
| Mar 31, 2025 | 20.57% |
| Dec 31, 2024 | 16.81% |
| Sep 30, 2024 | 23.15% |
| Jun 30, 2024 | 34.48% |
| Mar 31, 2024 | 27.80% |
| Dec 31, 2023 | 31.64% |
| Sep 30, 2023 | 29.99% |
| Jun 30, 2023 | 28.54% |
| Mar 31, 2023 | 21.59% |
| Dec 31, 2022 | 16.80% |
| Sep 30, 2022 | 25.80% |
| Jun 30, 2022 | 19.76% |
| Mar 31, 2022 | 22.39% |
| Dec 31, 2021 | 18.71% |
| Sep 30, 2021 | 21.91% |